PMS19 COST-EFFECTIVENESS OF USING ETANERCEPT AS FIRST LINE IN SEVERE AND HIGHLY ACTIVE RHEUMATOID ARTHRITIS (RA)
| Autor: | B Fautrel, Al. Ollivier, Jp. Daures, M Maravic, F Maurel, C Le Pen, H Miadi-Fargier |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
business.industry Cost effectiveness Health Policy First line Public Health Environmental and Occupational Health Alternative medicine medicine.disease Etanercept Rheumatoid arthritis Health care medicine Physical therapy Intensive care medicine business Pharmaceutical industry medicine.drug |
| Zdroj: | Value in Health. 11:A541-A542 |
| ISSN: | 1098-3015 |
| DOI: | 10.1016/s1098-3015(10)66787-3 |
| Popis: | ISPOR 11th Annual European Congress : "Moving and Improving Concepts & Evidence for Health Care Decisions", 11-2008, Athenes, Grece |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect